Business Wire·Aug 6, 2026, 4:02 PM ET

Janux Therapeutics Reports Second Quarter 2026 Financial Results and Business Highlights

Janux Therapeutics reported financial results for the quarter ended June 30, 2026, with $970.9 million in cash, cash equivalents, and short-term investments.
JANX007 Phase 1b enrollment continues in taxane-naïve monotherapy cohorts for metastatic castration-resistant prostate cancer (mCRPC).
An expansion cohort evaluating JANX007 in combination with darolutamide is actively enrolling taxane-naïve mCRPC patients.
JANX014 Phase 1 study continues enrolling patients with mCRPC to evaluate safety, pharmacokinetics, and antitumor activity.
JANX011 Phase 1 healthy volunteer study is progressing as planned to assess potential autoimmune disease treatments.
JANX013 remains on track for clinical initiation in the second half of 2026.
Initial clinical data from the JANX011 healthy volunteer study is expected in the second half of 2026.
Additional clinical data for JANX007 is expected to be announced at a medical congress in the first half of 2027.
Research and development expenses were $31.0 million for the quarter, compared to $34.7 million in the same period in 2025.
General and administrative expenses were $11.0 million for the quarter, compared to $10.5 million in the same period in 2025.
The company reported a net loss of $22.0 million for the quarter, compared to $33.9 million in the comparable period in 2025.
Collaboration revenue for the quarter was $10.3 million, with no comparable revenue in the prior year period.